All In Biotech

Drug Trial Radar · NCT06642961

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 19, 2022

Primary completion

Mar 31, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of GR1802 injection in comparison to placebo in patients with atopic dermatitis. Patients will receive GR1802 injection or Placebo every 2 Weeks.

Conditions

  • Asthma

Interventions

  • GR1802 injectionDrug

    GR1802 will be administered SC.

  • GR1802 injectionDrug

    GR1802 will be administered SC.

  • PlaceboOther

    The placebo will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in pre-bronchodilator FEV1 (forced expiratory volume in 1 second) at 12 weeks.Time frame: 12weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.